A Patient-Derived Xenograft Model of Glioblastoma

Chirayu R Chokshi; Neil Savage; Chitra Venugopal; Sheila K Singh

doi:10.1016/j.xpro.2020.100179

A Patient-Derived Xenograft Model of Glioblastoma

STAR Protoc. 2020 Nov 21;1(3):100179. doi: 10.1016/j.xpro.2020.100179. eCollection 2020 Dec 18.

Authors

Chirayu R Chokshi¹, Neil Savage¹, Chitra Venugopal², Sheila K Singh^{1

2}

Affiliations

¹ Department of Biochemistry, McMaster University, Hamilton, ON L8S 4L8, Canada.
² Department of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada.

Abstract

Glioblastoma (GBM) remains the most common malignant primary brain tumor in adults with a median survival of less than ~15 months. Further understanding and therapeutic development rely on the use of clinically relevant models of GBM. Here, we present our patient-derived in vitro and in vivo models that enrich for GBM stem cells (GSCs), a subpopulation of tumor cells with stem cell-like properties that recapitulate the cellular heterogeneity of its parental tumor and resist conventional therapy and seed disease relapse. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).

Keywords: Cancer; Cell culture; Cell isolation; Model Organisms.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Brain / pathology
Erythrocytes / metabolism
Glioblastoma / pathology*
Humans
Mice
Neoplastic Stem Cells / pathology
Specimen Handling
Tumor Cells, Cultured
Xenograft Model Antitumor Assays / methods*

Grants and funding

CIHR/Canada